Bausch + Lomb/$BLCO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Bausch + Lomb
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes brands like Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xiidra and Miebo that treat various eye complications.
- Ticker
- $BLCO
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 13,000
- Headquarters
- Vaughan, Canada
- Website
- www.bausch.com
Bausch + Lomb Metrics
BasicAdvanced
$7.1B
-
-$0.31
0.56
-
Price and volume
Market cap
$7.1B
Beta
0.56
52-week high
$21.36
52-week low
$14.44
Average daily volume
857K
Financial strength
Current ratio
1.559
Quick ratio
0.847
Long term debt to equity
0.776
Total debt to equity
0.783
Interest coverage (TTM)
1.33%
Profitability
EBITDA (TTM)
914
Gross margin (TTM)
61.41%
Net profit margin (TTM)
-2.05%
Operating margin (TTM)
7.49%
Effective tax rate (TTM)
-2,475.00%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
2.29%
Return on equity (TTM)
-1.58%
Valuation
Price to revenue (TTM)
1.314
Price to book
1.11
Price to tangible book (TTM)
-5.08
Price to free cash flow (TTM)
28.244
Free cash flow yield (TTM)
3.54%
Free cash flow per share (TTM)
0.708
Growth
Revenue change (TTM)
8.88%
Earnings per share change (TTM)
-63.68%
3-year revenue growth (CAGR)
10.93%
3-year earnings per share growth (CAGR)
-18.99%
What the Analysts think about Bausch + Lomb
Analyst ratings (Buy, Hold, Sell) for Bausch + Lomb stock.
Analyst projections of the future price of Bausch + Lomb stock.
Bulls say / Bears say
Third-quarter revenue rose 8% on a constant-currency basis, with growth across all three segments. MIEBO revenue rose 42%, daily silicone hydrogel lenses 24% and premium intraocular lenses about 70%, giving the company several active growth drivers. (Business Wire)
Adjusted EBITDA increased 34% and its margin expanded to 23.6%; free cash flow reached $178 million in the quarter. Net leverage fell to 4.1 times from 5.7 times a year earlier, showing that stronger operations are translating into cash and debt reduction. (The Motley Fool)
Management raised its 2026 revenue and adjusted EBITDA outlook for the third time this year. The new ranges are $5.45–$5.55 billion in revenue and $1.09–$1.14 billion in adjusted EBITDA, signalling confidence in continued momentum. (Business Wire)
Net leverage remains high at 4.1 times, and management expects about $365 million of interest expense for 2026. That substantial financing burden could limit cash available for investment and shareholder returns even as debt falls. (The Motley Fool)
An FDA inspection of the Tampa facility reportedly found persistent microbiological contamination in aseptic production areas. Any remediation or regulatory action could disrupt manufacturing and weigh on products that depend on those facilities. (Investing.com)
The pivotal study for the enVista Beyond lens narrowly missed predefined performance targets for depth of focus and intermediate vision. The company must review the results and consult regulators, creating uncertainty over the timing and prospects for this product opportunity. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2026.
Bausch + Lomb Financial Performance
Revenues and expenses
Bausch + Lomb Earnings Performance
Company profitability
Upcoming events
No upcoming events
Bausch + Lomb News
AllArticlesVideos
What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call
MarketBeat1 week ago
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
Business Wire4 weeks ago
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
Business Wire1 month ago
Funds containing Bausch + Lomb
Fund name | Fund size | $BLCO weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.07% |
iShares Ageing Population£AGES | $953M | 0.07% |
iShares Ageing Population€AGED | $903M | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.